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Abstract
Morbidity and mortality after a cerebrovascular event have increased during the
past few years, even after extensive efforts have been made concerning research in
prevention, acute treatment, pharmacotherapy, revascularization, and rehabilita-
tion. The functional deficits that arise from an ischemic event are related to the
increasing chronic disability that results from lower mortality rates. More people
are becoming chronically disabled; currently, as much as 90% of survivors are
affected and face difficulties to continue with daily life activities. In this chapter, we
briefly review the pathophysiology of ischemia and immediate clinical attention to
the event. We argue about the need to seek new pharmacological and non-
pharmacological alternatives and discuss the most representative in the field of
neuroprotection and neurorestoration. In addition, we review the most relevant
dietetic strategies and physical rehabilitation therapies, all aimed at improving the
survivors’ quality of life.
Keywords: cerebral ischemia, neuroprotection, neuroregeneration, rehabilitation,
immunomodulation
1. Introduction
Acute ischemic stroke (AIS) remains the second cause of death worldwide [1],
despite showing a mortality rate reduction of 1.19% [2]; only in 2017, there were 6
million 167, 291 deaths; 1, 291,000 more with respect to 1997. During the same
period, the survival rate increased by 0.02%; this caused an increment in
the disability-adjusted life years percentage (DALYs), which went from
4.17 to 5.29% [2].
Data from the World Health Organization (WHO) indicate that stroke repre-
sents the third cause of permanent adult disability worldwide [3], and is present in
90% of survivors. Motor deficits after stroke account for the high rates of long-
lasting disability. The most common impairments are related to speech, or language
and communication disorders (aphasia and dysphasia), apraxia [4], swallowing,
depression, cognitive impairment, and hemiparesis of the contralateral limb [5]
characterized by muscle weakness or spasticity in distal rather than proximal mus-
cles [6]. These deficits ultimately cause chronic disability, affecting the ability to
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work and the patient’s independence and autonomy for performing daily life
activities such as dressing or eating, ensuring they will require long-lasting care,
which also deteriorates their quality of life and that of the patients’ caregivers.
Stroke complications represent a considerable economic burden both individu-
ally and as a society; such complications are associated with a substantial increase in
household expenses related to a higher requirement of medical attention, medica-
tion, lost workdays, and payment to external or additional caregivers, and in several
cases, physical rehabilitation. It is estimated that the United States alone had an
annual expenditure of 45.5 billion dollars during the 2014–2015 period, which is
only expected to increase through 2035, according to estimations of RTI
international [7].
It is therefore fundamental to revisit the procedures regarding basic and clinical
research points of view, as well as the most recent recommendations issued by the
American Heart Association/American Stroke Association (AHA/ASA), which
endorse multiple-component quality improvement initiatives including emergency
department education and multidisciplinary teams with neurological management
experience, thus increasing the application of fibrinolytic treatment IV.
The strategies that are currently being studied in search of treatments for cere-
bral ischemia can be categorized into four areas: clinical care, neuroprotection,
neurorestoration strategies, and rehabilitation therapy.
The term neuroprotection is defined as the intentional intervention, either inhi-
bition or modulation, that takes place at a certain point during the ischemic cascade,
to intervene in a specific mechanism of damage to prevent tissue injury from
increasing during the acute phase of ischemia [8]. The neurorestoration is devel-
oped through the stimulation of neurogenesis and neuroplasticity to restore the
tissue and functional integrity of the neural tissue.
In the clinical setting, several recanalization strategies have been explored to
restore blood flow to the injured area of tissue as soon as possible, to assure the
lesser damage and decrease secondary sequelae to the original lesion. Finally, phys-
ical therapy has become a rehabilitation tactic that has positively impacted the
recovery of patients’ independence, autonomy, and quality of life, which is worth
reviewing.
2. Pathophysiology of stroke
Cerebral ischemia is caused by an abrupt and sustained occlusion of blood flow
to a large artery that unties a series of biochemical alterations that are known as the
ischemic cascade, Figure 1 [9]; during the development of such changes, a set of
mechanisms that lead to cell death occurs: ionic imbalance and excitotoxicity,
oxidative stress, and inflammation [10].
The reduction of blood flow leads to a depletion in levels of glucose and O2,
which alters aerobic metabolism, increasing lactic acid accumulation. Simulta-
neously, astrocytes use stored glycogen to provide energy to the neurons in the
form of lactate [11]; but, because aerobic metabolism is interrupted at this time,
lactic acid continues to accumulate, causing lactic acidosis, which causes ionic
dysfunction [12]. Ionic alterations, together with Na+/K+ pump inactivity, give rise
to neuronal depolarization, which leads to the opening of the Ca2+ channels and the
subsequent release of excitatory neurotransmitters such as glutamate, causing
increased activation of ionotropic receptors, especially NMDA, increasing the Ca2+
flux into the cell [13].
Ca2+ is an essential protagonist within the ischemic cascade since it is capable of
activating a significant amount of proteins that lead to cell death, and
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overproduction of free radicals; such proteins are calpains [14], endonucleases [15],
calmodulin [16], and A2 phospholipase (Figure 1) [17]. Activation of these proteins
leads to a further increase in free radical production and other oxidant species that
directly damage structural molecules and activate inflammatory processes [18].
The mitochondria are where the highest production of free radicals takes place;
under normal conditions, superoxide anion (O2
) and hydrogen peroxide (H2O2)
are produced continuously and eliminated by antioxidant enzymes such as super-
oxide dismutase (SOD), catalase, and glutathione peroxidase [19]. Alternatively,
under ischemic conditions, reperfusion provides sufficient substrate for different
enzymatic oxidation reactions to take place, causing an overproduction of free
oxygen radicals (ROS) and the inactivation of antioxidant enzymes [20]. Concur-
rently, nitric oxide (NO) increases due to the activation of endothelial and neuronal
nitric oxide synthases as a result of increased Ca2+ concentration, NO reacts with
ROS and forms a highly toxic peroxynitric acid (ONOOH) [21].
Free radicals promote mitochondrial membrane permeability and allow for
cytochrome c to be released into the cytosol, where the intrinsic pathway of apo-
ptosis becomes activated, the concentration of free radicals also increases lipid
peroxidation and protein denaturalization [22], DNA fragmentation, and activate
several signaling pathways that lead to neural death, such as PI3K/AKT [23], Bcl2,
p53 [24] and others. From the moment of the occlusion, endothelial cells express
damage-associated molecular patterns (DAMPs), produce ROS and adhesion mole-
cules that allow for their activation and that of surrounding mast cells and macro-
phages, which, as a consequence, release histamine, proteases, TNF-a, and
Figure 1.
Key points to the pathophysiology of stroke.
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chemokines [25]. The production and release of these molecules promote the blood-
brain barrier (BBB) rupturing, thus causing peripheral leukocyte invasion into the
injured brain parenchyma [26].
Microglial cells are then activated in the non-perfused region of the brain
parenchyma [27], microglial cells acquire phagocytic characteristics and a predom-
inantly pro-inflammatory phenotype (M1), which in turn increases the release of
interleukin-6 (IL-6), interleukin 1β (IL-1β), tumor necrosis factor-alpha (TNF-α),
NO molecules, and prostanoids [28]. Peripheral immune cells such as neutrophils,
B lymphocytes, T lymphocytes, and NK are recruited into the injured tissue, this
event is thought to contribute both beneficially by inducing the release of anti-
inflammatory cytokines and growth factors, and negatively by increasing the lesion
through a sustained release of proinflammatory cytokines and free radicals [29].
Within the process of the ischemic cascade, three points are identified that could
classify as strategic to restore neuroprotection (ionic imbalance, excitotoxicity, and
inflammation); nonetheless, most neuroprotective drugs act in many of the phases
of the ischemic cascade, which is why they cannot be classified into a single step of
neuroprotection.
3. Current stroke management in the clinical setting: the first
step after the stroke
Early diagnosis of stroke is a predictor for better clinical outcomes [30]; there-
fore, its confirmation is a pressing matter for the treatment to begin as soon as
possible from the recognition of symptoms onset [31]. Currently, different strate-
gies for acute ischemic stroke are being used in the clinical setting and are part of
the AHA/ASA clinical practice guidelines [32].
The differential diagnosis for stroke includes transient ischemic attacks, seizure,
syncope, migraine, and brain tumors [33]. To establish a correct and timely diag-
nosis and to determine the best course of action, the clinician must rely on labora-
tory testing [34] (blood glucose is usually high, total cholesterol, LDL, HDL, AST,
CPK-MB), and although the gold standard for diagnosis is a cerebral angiography,
clinicians try to avoid it by choosing different methods such as imaging testing,
including the first-line non-contrast CT scans, CT angiography, MRI, and MRI
angiography [32, 35, 36]. In the earliest stages of acute stroke, CT scans are less
useful for ischemic stroke diagnosis but can rule out hemorrhagic stroke [36]. Other
clinical tests such as EKG, EEG, and the National Institutes of Health Stroke Scale
(NIHSS) help establish differential diagnosis and treatment plan [35].
Specific and timely reperfusion treatment is essential to determine the course of
the clinical outcome and to improve survival. Once the ischemic etiology has been
established, and the patient is stable, treatment should start promptly. Currently,
two major therapeutic strategies are being used to treat cerebral ischemia to allow
for recanalization and reperfusion. The treatment of choice will depend on time to
treatment and etiology of the injury; these therapies are thrombolysis using phar-
macological agents and mechanical thrombectomy [35, 37–39].
At present and still after decades, the FDA only approves the use of recombinant
tissue plasminogen activator (rTPA), also known as alteplase, as the sole pharma-
cological option for recanalization [35, 39]. Alteplase initiates local fibrinolysis
when administered intravenously by hydrolyzing the peptide bond in plasminogen
to form plasmin [40]. The standard IV dosage is 0.9 mg/kg for 60 min, with a 10%
bolus over 1 min within 4.5 h of AIS onset [31].
Although alteplase is the only drug available for thrombolysis, most stroke
sufferers do not receive this drug as treatment. There usually is a delay in
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recognition of the symptoms and the time window in which rTPA must be admin-
istered is from 3 to 4.5 h from onset of symptoms, and benefits diminish over time
[39, 41], which is why the new AHA/ASA guidelines recommend not waiting for
clinical improvement before administration [32]. Also, not all patients are eligible,
since candidates must be ≤80 years of age, without diabetes or stroke history, with
an NIHSS score ≤ 25, not currently taking oral anticoagulation, and without
radiologic evidence of ischemic injury involving more than one-third of the MCA
territory [42].
Complications that are associated with its use are limited: BBB integrity alter-
ations, and hemorrhagic transformation, granting that other studies have shown it
to be well tolerated by patients using warfarin or other anticoagulants [38], in
controversy with the new AHA/ASA guidelines that suggest it should not be
administered if the patient received heparin 24 h before [32, 35, 43]. Other drugs
are also available, such as aspirin, which must be delivered within 24–48 h after
stroke onset. Although the guidelines emphasize that it should not be used to
replace mechanical thrombectomy or IV alteplase, aspirin continues to be the choice
for secondary prophylaxis [32, 44], even when the 2018 guidelines find no benefit
from its use for the treatment of an ongoing AIS [32].
Furthermore, the FDA approves of endovascular treatments, which are reported
to have a time window of up to 8 hours from the onset of symptoms [38].
For patients with large vessel occlusion, less responsive to rTPA, intra-arterial
therapy is recommended, since it leads to higher recanalization rates by being able
to infuse the drug directly into the occluded area or the clot itself [35, 45]. About
10% of patients with AIS fall into this category, but only a few centers can perform
endovascular procedures in proper conditions [46].
Also, endovascular mechanical thrombectomy using contact aspiration (CA) [47],
which has been described before [48], and stent retrievers (SR), especially those of
new generations [49], for clot rupturing and aspiration has shown significant bene-
fits in large vessel occlusion [50] regarding clinical outcomes and lower complication
rates [49]. Notwithstanding, CA alone, without the use of a SR, is associated with a
greater need for rescue treatment, and thus, worse outcomes [51]; the SR might also
increase the risk for hemorrhagic transformation and neurological deficit [52].
Increased costs of endovascular treatments, as well as their complexity and need
for trained personnel, cause patients to have less access to them. Therefore,
exploring new pharmacological therapies should be continued.
4. First neuroprotective pharmacological and non-pharmacological
treatments
In the search to find new alternatives of neuroprotective agents, a great variety
of molecules have been explored that affect one or several strategic points of the
pathophysiology, and that promise good results; some are mentioned below.
During the onset of AIS, glucose and oxygen concentrations decrease, and this
promotes the activation of adenosine monophosphate-activated protein kinase
(AMPK). This process upregulates cellular pathways that control energy metabo-
lism through catabolic pathways such as glycolysis and lipid oxidation to increase
adenosine triphosphate (ATP) production and decrease its consumption through
the inhibition of gluconeogenesis. Observations have been made regarding the fact
that the activation of this enzyme for short periods increases neural survival, but its
activation for extended periods will lead to cell death through apoptosis, necrosis,
and autophagy [53], which is why several drugs that modulate AMPK activation
have been tested recently in search for beneficial effects.
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To mention some, metformin has been widely studied for cerebral ischemia
since it possesses pleiotropic activity and modulates AMPK activation [54]. In 2016,
Zhang et al. administered 7 mg/kg of metformin intraperitoneally to C57BL/6 mice
for 7 days, before middle cerebral artery occlusion (MCAO). After MCAO, the
authors observed that it induced neuroprotection by reducing infarct size, through
lower AMPK, results that were not observed if administered for short periods of
1–3 days before MCAO, or after the occlusion; also, these benefits were not found in
the case of reperfusion [55]. Also, the neuroprotective effect of metformin was
observed in a global ischemia model in rats; after administration, apoptosis
decreased, and mitochondrial biogenesis was induced [56]. Other experiments have
demonstrated that metformin has the potential to improve memory and learning
through the increase in brain-derived neurotrophic factor (BDNF) and p7056k
protein [57]. On the other hand, it has also been implicated in the reduction of IL-6,
IL-1β, TNF-α, and adhesion molecule levels, as well as a decrease in neutrophil
infiltration [58]. Considering these results, it is crucial to clarify how this modula-
tion is carried out since there is some controversy about the mechanism (Table 1).
Atorvastatin is a statin that has pleiotropic effects, since it allows angiogenesis
and synaptogenesis, increases blood flow, blunts atherosclerotic plaque formation,
and provides neuroprotection in cerebral ischemia model [59] by reducing
aquaporin 4 expression (AQP4) [60], thus, preventing cerebral edema and the
increase of infarct size. This statin has also been reported to attenuate cognitive
deficit [61] through caspase 3 inhibition and avoiding neural death in the CA1
region of the hippocampus.
There is also a great variety of neuroprotective drugs or molecules that act closer
by modulating inflammation, through the promotion of an anti-inflammatory
microglial phenotype activation; only the most representative will be mentioned
below.
DRα1 recombinant protein linked to the MOG peptide has demonstrated the
ability to decrease macrophage migration and monocyte activation through its
binding to CD74, which translates to a reduction in infarct size [62]. It has also been
shown that it reduces proinflammatory cytokine expression, such as IL-1β, I-17,
TNF-α, and INF-ϒ, as well as lowers T lymphocyte infiltration and promotes a
polarization toward an M2 phenotype macrophage activation [63].
Cop-1 or glatiramer acetate is a copolymer formed by four amino acids
(L-alanine, L-lysine, L-glutamic, and L-tyrosine) that has shown to exert
neuroprotective effects by being able to reduce infarct size and improve neurolog-
ical deficit [64]. Cop-1 increases the expression of IL-10, BDNF, Insulin-like growth
factor-1 (IGF-1), and neurotrophin (NT-3) in the choroid plexus [65], and the
cortex, which stimulates greater neurogenesis [66]. Mangin et al. and their study
group obtained similar results; they reported that Cop-1 is capable of reducing
COX-2, CD32, TNF-α, and IL-1β, as well as inducing greater neurogenesis and thus,
reducing memory loss in mice with cerebral ischemia [67].
On the other hand, food strategies have also been proposed; for example, diet-
induced ketosis has demonstrated its neuroprotective effects. Xu et al. observed, in
2017, that the ketogenic diet induced a reduction in infarct size through the
overexpression of transcription factors HIF-1α, pAKT, and AMPK [68]; in 2018
Stefanovic, beneficial effects of administering exogenous β-hydroxybutyrate intra-
peritoneally were also observed in a model of cerebral ischemia induced by
endothelin-1 in rats. He reported that the ischemic penumbra cells had a diminished
glucose uptake, which translated into less ROS production, astrogliosis, and neuro-
nal death [69]. Ketone bodies or ketosis is worth further exploration since clinical
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Drug Mechanism Observed effect Authors
Metformin AMPK
Apoptosis
Infarct size
Neurological deficit
Deng et al. [55]
AMPK
Apoptosis
Infarct size
Neurological deficit
Ashabi et al. [56]
AMPK
BDNF
P70S6K
Memory
Learning
Ghadernezhad et al. [57]
AMPK
NFkβ
IL-6
IL-1β
TNF-α
ICAM
Neutrophils
Protection of blood-brain
barrier
Liu et al. [58]
Atorvastatin Aquaporin AQP4 Infarct size
Neurological deficit
Edema
Cheng et al. [60]
pJNK3
Caspase 3
CA1 neurons of the
hippocampus
Shao et al. [61]
Ketosis HIF-α
AMPK
pAKT
Infarct size
Neural survival
Xu et al. [68]
ROS
Astrogliosis
Neural survival Bazzigaluppi et al. [69]
DHA Macrophages
Microglia
Leukocyte infiltration
TNF-α
IL-6
IL-1β
Infarct size
Edema
Protection of blood-brain
barrier
Chang et al. [70]
Macrophages
Neutrophils
T lymphocytes
B lymphocytes
Infiltration
Polarization of
macrophages to M2
Infarct size
Neurological deficit
Cai et al. [71]
Neurogenesis Infarct size
Neurological deficit
Belayev et al. [72]
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trials in Alzheimer’s patients with mild cognitive decline have shown improvements
in verbal memory after being treated with a ketogenic diet [73].
Dietary administration with docosahexaenoic acid (DHA) has also proven to
have anti-inflammatory and neuroprotective effects in cerebral ischemia through
the reduction of proinflammatory cytokine expression, such as TNF-α, IL-1β and
IL-6; even, a decrease in macrophage and microglial activation and a decrease in
leukocyte infiltration to the lesion site [70]. Similar observations were made by Cai
et al. who noted that macrophage, neutrophil, and T and B lymphocyte infiltration
was significantly decreased, besides stimulating an anti-inflammatory macrophage
(M2) activation [71]; DHA is also capable of inducing neurogenesis and angiogene-
sis [72], which makes it a promising molecule for future experimental research.
5. Neurorestoration
Many of the cytokines and growth factors that result from immunomodulation
processes are directly involved in neurorestoration processes, the latter understood
as the set of strategies that seek to reconstruct the affected neural circuits through
neuroplasticity or neurogenesis [74].
Drug Mechanism Observed effect Authors
DRα-
1MOG35-55
Macrophages migration
Monocytes
Infarct size Benedek et al. [62]
TNF-α
IL-17
IL-1β
INF-ϒ
T lymphocytes
Infiltration
Infarct size
Motor functions
Wang et al. [63]
Cop-1 Immunomodulation Infarct size
Neurological deficit
Ibarra et al. [64]
IL-10
BDNF
IGF-1
NT-3
Neurological deficit Cruz et al. [65].
Neurogenesis
NT-3
Neurological deficit Cruz et al. [66]
COX2
Cd32
TNF-α
IL-1β
Infarct size
Neurological deficit
Edema
Memory
Mangin et al. [67]
, regulation ; , activation.
Table 1.
Main neuroprotective agents in ischemia.
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Neurotrophins are a group of proteins that are involved in the maintenance and
survival of the central nervous system [75]; this includes BDNF, NT-3, NT-4, NT-5,
nerve growth factor (NGF), and IGF-1. Neurotrophins interact with two types of
receptors, Trk (tyrosine kinase receptors) and the p75 receptor that belongs to the
TNFR receptor family, implicated in apoptosis processes.
Among the most studied neurotrophins are BDNF and NT-3; BDNF is produced
by almost all brain cells and is known to participate in processes of proliferation,
survival, and neuronal differentiation. Its receptors are widely distributed [76] and
activate critical signaling pathways such as PLCγ, PI3K, and ERK, which ultimately
lead to phosphorylation and activation of the transcription factor CREB that medi-
ates the expression of genes that are essential for the survival and differentiation of
neurons [77]. NT-3 has also been involved in the processes of cell proliferation and
differentiation through the notch pathway [78], as well as participating in processes
of memory and learning [76].
Experiments have shown that the increase of neurotrophic factors in the ische-
mia model is commonly related to a better functional or memory recovery and that
it is usually associated with neurogenesis or neuroplasticity—as in the case of
metformin, which showed an increase in BDNF expression and that induced a more
significant recovery of memory and learning [57]. Also, Cop-1 was able to induce
the increase of BDNF, IGF-1, and NT-3; which correlated with the increase in
neurogenesis [65]; and the experiments of Luan et al. showed that patients with
cerebral ischemia who presented higher levels of NGF obtained a better functional
recovery at 3 months after the ischemia [79].
Stem cell transplantation has also been linked to better neurological recovery;
although clinical trials have not reported the expected results [80], basic research
using stem cells has shown an increase in neurological rehabilitation and suggested
mechanisms include the overexpression of BDNF and IGF-1 [81, 82], as well as
immunomodulatory cytokines like IL-10, which together induce a polarization
toward an anti-inflammatory M2 microglial phenotype [83].
In recent years, there has been an increase in the interest of studying how the
external environment has a direct effect on the structure and neuronal function,
that is, on neuroplasticity [84], and that is why researchers keep studying what kind
of external characteristics (specifically physical and social activity) can increase
these factors and thereby obtain more significant benefits.
In 2017, Chen et al. explored whether a specific type of environment stimulated
the production of BDNF in rats with cerebral ischemia, and what they observed was
that physical stimulation increases the expression of neurotrophic factors more than
social stimulation and obtains a higher neurological recovery [85]. Mang, on the other
hand, observed that the increase in BDNF after an ischemic event is determined by
the type of aerobic exercise and the val66met variant of the BDNF gene [86].
The effects on NT-3 have also been evaluated, and the results have been very
similar; there is an increase in its levels with physical stimulation after the ischemic
event and a more significant functional recovery [87]. Other proteins have also been
associated with neuronal plasticity through axonal growth, such as the growth-
associated protein 43 (GAP-43), which has been observed to increase when rats
with cerebral ischemia undergo fastigial electrostimulation [88].
Electrical stimulation directly into the fastigial nucleus (FNS) has proven to be
beneficial in a model of MCAO [89]. The mechanism through which FNS has shown
to improve walking balance and neurological scores is due to the activation of the
PKA/cAMP pathway, suppressing the expression of Rho-Kinase, and through the
overexpression of GAP-43 protein [89].
In this sense, experiments continue to be designed to establish the efficacy of
training types and times to modulate inflammation, the production of
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neurotrophins, and the impact on patient mobility, as in the proposal developed by
Scalzo et al. [89] that gives rise to the continued development of a well-founded
physical therapy for patients with cerebral ischemia.
6. Physical therapy as a coadjuvant to neural restoration through
stimulation of neural plasticity
Post-stroke physical rehabilitation (PR) is of utmost importance as a non-
pharmacological strategy for neuroprotection and neurorestoration but, most sig-
nificantly, should be aimed at restoring and regaining motor impairment during the
chronic period [90], and to promote the functional autonomy of the patient [4].
Recovery of body function assessment depends on whether the patients can per-
form everyday activities on their own and is measurable by several different scales
such as UE-FM score for the upper extremity, and the Barthel Index for Activities
for Daily Living scale [4].
Functional and cognitive deficit severity is related to tissue integrity [91], and it
is not clear whether recovery results from biological processes or physical rehabili-
tation [91, 92]. Some clinical parameters that can be observed at the bedside, such as
early finger extension and shoulder abduction, can act as predictors of long-term
(over 6 months) recovery after stroke [93]. Spontaneous recovery of upper and
lower limbs occurs depending on the type, location, and severity of the lesion, in
approximately 60–70% of cases [93] during the first 2–6 months [4, 94], period
after which most people believe they have achieved maximal recovery and stop
with either physical or pharmacological therapy [4, 95]. Interventions should be
designed according to the stage of neurological recovery the patient is in, with the
consideration that early chronicity is not a contraindication for continuing
rehabilitation [4].
Physical rehabilitation must start early, if possible, during the first week post-
stroke [96], because there is an intensification in neuroplasticity during the early
stages [91], employing different mechanisms such as the axon regeneration [88],
and the higher expression of growth-promoting genes, such as GAP-43. This lesion-
induced plasticity that happens during the first days post-stroke [90, 97, 98]
reportedly lasts around 6 months after stroke [4, 91, 95, 97]. Also, therapy must
continue after such a period, to take advantage of behavior-induced plasticity [95],
which is still possible after 1 year of having had the stroke [4].
PR has also been proven to elicit neuroprotection and neurorestoration in other
neurological disease models, such as Parkinson’s, through the upregulation of BDNF
and GDNF and prevention of inflammatory response [99]. The following therapies
are currently under study for neurorestorative purposes during the post-stroke
chronic period:
Environmental enrichment focuses on inducing adaptation to different environ-
ments, including toys and complex tasks, to improve functional outcomes [97].
Also, this type of therapy has shown to enhance angiogenesis by increasing CD31
and VEGF [97]. Furthermore, environmental enrichment upregulates BDNF secre-
tion, and other neurotrophic factors [85, 90].
Wang et al. found improvements in spatial learning and memory, number of
synapses, and an increase in the expression of synaptogenesis markers. GAP-43, a
protein involved in neural plasticity through axonal growth, is upregulated during
the first 28 days after stroke in mice exposed to environmental enrichment. Like-
wise, other markers involved in synaptogenesis like SYN and PSD-95 achieve better
concentrations in the brains of mice treated with environmental enrichment [97].
10
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Functional electrical therapy has been used alongside other types of electrical
stimulation to induce repetitive muscular contraction to mobilize certain joints [6].
Somatosensory stimulation might enhance neurorehabilitation after stroke through
the stimulation of corticomotoneuronal excitability [6]. It has been proposed that
this type of therapy increases muscle strength, reduces spasticity, and facilitates
voluntary movements, among other motor benefits [6].
Guided self-rehabilitation (GSR) is a method in which the intensity of training
can be increased inside the home environment. While combined with conventional
rehabilitation, it has proven to be efficacious in engaging the patients in their
recovery through a contract between the patient and the therapist, allowing for an
increased sense of responsibility and motivation for the patients, who are required to
register their progress in a diary [100]. Although not many physical therapists accept
such an approach [100], positive changes have been observed after 1 year of GSR and
conventional rehabilitation in ultrasound measuring of the soleus’ and medial gas-
trocnemius’ thickness and fascicle length, as well as clinical improvement, observed
in soleus extensibility and ambulation speed [101] in chronic stroke patients.
Constraint-induced therapy requires constraining the non-affected limb for 90%
of the waking hours, forcing the patient to use the paretic limb, inducing the
increase of use-dependent plasticity, although this therapy is not practical for most
of the population [6].
Videogame- or virtual reality-based (VRb) therapies have been under study for
upper extremity functional recovery in acute and subacute or chronic patients
[91, 96, 99, 102]; the rationale for such approaches is that they promote motor
learning and repetitive, intense movements, and in the specific case of virtual
reality, the patient is exposed to interactive visual, auditive, and proprioceptive
feedback [91, 102]. Different videogame and VRb therapies have reported
improvements in fine dexterity, grip strength [96], and grasp force [99] in upper
extremities, and, activities of daily living [91] and cognition [102] in young and
elderly patients after several weeks of rehabilitation. Better results have been
observed when combined with conventional therapy, although it is still not known
whether it enhances or speeds up recovery [91].
7. Final remarks and future directions
In addition to continuing the search for pharmacological agents that allow the
neuroprotection and neurorestoration of tissue affected by cerebral ischemia, the
development of physical therapy and diet modification offers new horizons that
have shown satisfactory results in the clinical setting in short times. However, it has
not yet been possible to establish a protocolized treatment that can be added to the
health care guidelines; so it is important to continue exploring all possible strategies
to improve the quality of life of people who have suffered a cerebral infarction and
that of their caregivers.
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